A Phase I Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 1, 2020

Primary Completion Date

March 13, 2023

Study Completion Date

December 25, 2023

Conditions

Neuromyelitis Optica Spectrum Disorders

Interventions

DRUG

BAT4406F

"Open-label dose escalation starting from 20mg.~Route of administration: intravenous infusion."

Trial Locations (1)

Huashan Hospital affiliated to Fudan University, Shanghai